Compare ZJYL & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZJYL | NEPH |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.5M | 46.8M |
| IPO Year | 2023 | 2004 |
| Metric | ZJYL | NEPH |
|---|---|---|
| Price | $0.24 | $5.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.7M | 75.0K |
| Earning Date | 08-20-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.01 | ★ 0.14 |
| Revenue | ★ $22,826,624.00 | $17,930,000.00 |
| Revenue This Year | N/A | $24.38 |
| Revenue Next Year | N/A | $10.16 |
| P/E Ratio | ★ $21.46 | $38.10 |
| Revenue Growth | 13.42 | ★ 32.36 |
| 52 Week Low | $0.22 | $1.39 |
| 52 Week High | $1.42 | $6.42 |
| Indicator | ZJYL | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 31.88 | 54.24 |
| Support Level | $0.24 | $4.50 |
| Resistance Level | $0.28 | $5.63 |
| Average True Range (ATR) | 0.02 | 0.59 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 9.83 | 52.67 |
Jin Medical International Ltd offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other living aids products to be used by people with disabilities or impaired mobility. The company's products are sold to distributors in both China and overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, and nursing products. Geographically, it generates the majority of its revenue from Japan.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.